We are working from home under lockdown. Our team is continuously tracking the impact of COVID-19 across different industries and we will incorporate those insights in our reports. For any specific query, mail us at [email protected]
Lung Cancer Prognosis Market | Forecasts up to 2025 | Covid-19 Impact Analysis
This report, from Stratview Research, studies the global lung cancer prognosis over the trend period of 2014 to 2018 and forecast period of 2019 to 2025. The report provides detailed insights into the market dynamics to enable informed business decision making and growth strategy formulation based on the opportunities present in the market.
The Burning Questions this Report will Answer:
For the first time in market, one report exclusively touches upon the demands, gaps and opportunities of the global lung cancer market while covering Lung Cancer Diagnostics, Lung Cancer Therapeutics, Lung Cancer Nutritional supplement, Lung Cancer Surgery and Lung Cancer Connected Health Market. The management of Lung cancer varies with region, by decision makers, by site of treatment, by type of lung cancer, by age, by decision making process, by cost of therapy at each stage and by various other parameters. Why Lung Cancer? Because WHO and other health agencies consider it to be the number One killer across the world.
If we consider the Lung Cancer Management Market from the stakeholder’s perspective, then drugs approved for Small Cell Lung Cancer will not be applicable for Non-Small Cell Lung Cancer. What is the future of the top 10 best-selling drugs in this segment, will they stay or fade away? Among the class of drugs, will Angiogenesis Inhibitors take a dip in sales by 2025 or will it overtake the sales of drugs in the class Immune Checkpoint Inhibitors? What is the market for BRAF / MEK Inhibitors? Who all are the active players and who are newbies. Will the differential cost of therapeutics across the regions impact the drug sales in North America versus APAC? In the Small Scale Lung Cancer Therapeutics, immunotherapy drugs will play a major role in the next 7 years and may grow a CAGR of 7.44% globally however the same class of drugs might grow at a CAGR of 10.59% in the Non-Small Scale Lung Cancer Therapeutics Market in the same time period.
Considering that all the drugs mentioned above have a bright future till 2025, how many companies would like to compete in this market. How will the new joiners react if they consider that the market had a potential of USD 17.11 Billion alone in 2018 and is likely to grow at a CAGR of 8.28% globally till 2025.
In the Lung Cancer Diagnostics segment, Thermofischer, Roche, Biomerieux are few of the market leaders but are they going to get tougher competitions from the newbies such as Astraeus Technologies, Zebra Medical, Deton, Oncocyte and many more that are entering the specialized diagnostics market. It might be interesting to consider that while 50% of the oncologists decide (decision makers) the type of tests and the frequency of repeat tests, shared decision making process is equally high among the Lung Cancer Management Market. The opportunity is huge, NSCLC cases accounts for 85% of the recorded lung cancer incidence worldwide, > 60% require diagnosis, medicine for maintenance, pain and other side effects.
Considering the complications and limitations in lung cancer surgery (not all patients are eligible), still the market is expected to grow steadily at a CAGR of 6.29%, over the course of forecast period (2019-2025). The demand for NSCLC surgery is high, thus the market size of 99%. In some cases surgery is not recommended, when the tumor is found in proximity with the heart, the esophagus – the food pipe, the wind pipe and major blood vessels. The demand for NSCLC surgery is expected to grow rapidly with a CAGR of 6.31% over the course of seven years. The study on the Lung Cancer Management Market by Stratview also states that Lobectomy (sub segment under Lung Cancer Surgery) results in lowest recurrence rate and higher survival rate as compared to other surgery type. Hence it is the highly referred type of surgery procedure for NSCLC cases. One of the companies, Auris is most promising in this segment and has a brighter future ahead. This segment also foresees competition from Chinese companies such as IFLYTEK who are strong contenders in the global market.
Among the different segments of Global Lung Cancer Management Market, connected health or Apps for Lung cancer maintenance or management are few. However, the segment is promising, as researchers believe that App based software can help in treatment adherence, keeping track of medical records (insurance companies, medical centres). Developed markets such as USA, UK, Germany, France, Japan, China and Australia are the near term opportunities.
Lung cancer patients need nutritional supplements throughout their treatment phase followed by recovery and maintenance phase. The study from Stratview Research also looks at the aspects of sales and marketing, buying patterns of end users which can help companies such as Abbott, Danone, Nestle, B Braun and more gauge the market and look at the changing preferences of the market in regions such as Asia Pacific, Europe and North America.
Finally the report on Lung Cancer Prognosis also focuses on the regional aspects and gives the reader the flexibility to consider between global market as whole or regions in particular. It is imperative to look at this market as connected as out of the prevalent cases of Lung cancer are potential candidates of diagnosis and of the diagnosed pool a higher percentage will require medication or surgery, there will be few drop outs and few gaps, more or less all the above will need apps or Healthcare IT products to monitor drug adherence, doctor access, and above all long term nutritional supplement.
Hence, readers may consider this inter-linked market under the Lung cancer management market and consider the opportunities that exist in each segment from 2019-2025.
Our reports offer high-quality insights and are the outcome of detailed research methodology comprising extensive secondary research, rigorous primary interviews with industry stakeholders and validation and triangulation with Stratview Research’s internal database and statistical tools. More than 1,000 authenticated secondary sources, such as company annual reports, fact book, press release, journals, investor presentation, white papers, patents, and articles have been leveraged to gather the data. About 10 detailed primary interviews with the market players across the value chain in all four regions and industry experts have been executed to obtain both the qualitative and quantitative insights.
This report provides market intelligence in the most comprehensive way. The report structure has been kept such that it offers maximum business value. It provides critical insights into the market dynamics and will enable strategic decision making for the existing market players as well as those willing to enter the market. The following are the key features of the report:
The global lung cancer prognosis market is segmented into the following categories:
By Treatment Algorithm
By Demand & Supply
With this detailed report, Stratview Research offers one of the following free customization options to our first-time clients:
Custom Research: Stratview Research offers custom research services across sectors. In the case of any custom research requirement related to market assessment, competitive benchmarking, sourcing and procurement, target screening, and others, please send your inquiry at [email protected].